DVx Inc. Announces Non-Consolidated Earnings Results for the Nine Months Ended December 31, 2016; Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2017; Provides Dividend Guidance for the Year Ending March 31, 2017
February 01, 2017
Share
DVx Inc. announced non-consolidated earnings results for the nine months ended December 31, 2016. For the period, the company reported net sales of ¥26,028 million, operating income of ¥1,141 million, ordinary income of ¥1,116 million, profit of ¥770 million or net income per basic share of ¥68.34 compared to net sales of ¥22,588 million, operating income of ¥1,004 million, ordinary income of ¥1,006 million, profit of ¥983 million or net income per basic share of ¥87.19 for the same period last year. Profit before income taxes was ¥1,115,818 against ¥1,459,484 a year ago.
The company expects to pay year-end dividend of ¥23.00 per share for the fiscal year ending March 31, 2017.
For the full year of fiscal year ending March 31, 2017, the non-consolidated company expects net sales of ¥33,200 million, operating income of ¥1,536 million, ordinary income of ¥1,536 million, profit of ¥1,028 million or net income per basic share of ¥91.17.
DVx Inc. is a Japan-based company mainly engaged in the sale of medical equipment for circulatory system diseases. The Company operates in two business segments. The Arrhythmia segment mainly sells cardiac pacemakers, implantable cardioverter-defibrillators (ICDs), electrode catheters and ablation catheters. The Ischemia segment is engaged in the import and sale of automated contrast medium injectors under the name ACIST, excimer laser angioplasty systems, as well as sale of coronary artery stent products as agency business. The others business is engaged in the sale of neurosurgical products, general surgery related products, gastrointestinal related products, radiation protection supplies, among others.
DVx Inc. Announces Non-Consolidated Earnings Results for the Nine Months Ended December 31, 2016; Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2017; Provides Dividend Guidance for the Year Ending March 31, 2017